Vireo Growth (OTCMKTS:VREOD – Get Free Report) and Journey Medical (NASDAQ:DERM – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings.
Profitability
This table compares Vireo Growth and Journey Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vireo Growth | -23.37% | -19.76% | -7.15% |
| Journey Medical | -8.95% | -20.23% | -6.60% |
Insider & Institutional Ownership
7.2% of Journey Medical shares are owned by institutional investors. 3.8% of Vireo Growth shares are owned by insiders. Comparatively, 14.5% of Journey Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vireo Growth | $268.77 million | 1.68 | -$68.11 million | ($3.30) | -3.02 |
| Journey Medical | $61.86 million | 2.88 | -$11.43 million | ($0.22) | -28.68 |
Journey Medical has lower revenue, but higher earnings than Vireo Growth. Journey Medical is trading at a lower price-to-earnings ratio than Vireo Growth, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Vireo Growth has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500. Comparatively, Journey Medical has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Vireo Growth and Journey Medical, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vireo Growth | 1 | 0 | 0 | 0 | 1.00 |
| Journey Medical | 1 | 1 | 2 | 0 | 2.25 |
Journey Medical has a consensus price target of $14.00, indicating a potential upside of 121.87%. Given Journey Medical’s stronger consensus rating and higher probable upside, analysts plainly believe Journey Medical is more favorable than Vireo Growth.
Summary
Journey Medical beats Vireo Growth on 10 of the 14 factors compared between the two stocks.
About Vireo Growth
Goodness Growth Holdings, Inc. operates as a cannabis company in the United States. The company cultivates, processes, and distributes medical and adult-use cannabis products. It sells cannabis products through its network of Green Goods and other Goodness Growth branded retail dispensaries and third-party dispensaries in Maryland, Minnesota, and New York. The company was formerly known as Vireo Health International Inc. and changed its name to Goodness Growth Holdings, Inc. in June 2021. Goodness Growth Holdings, Inc. is headquartered in Minneapolis, Minnesota.
About Journey Medical
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.
Receive News & Ratings for Vireo Growth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vireo Growth and related companies with MarketBeat.com's FREE daily email newsletter.
